Mediolanum farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Mediolanum farmaceutici SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10918
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mediolanum farmaceutici SpA (Mediolanum) is a developer and supplier of pharmaceuticals products and prescription drugs. The company offers products in therapeutic areas, which include neuropsychiatric, osteoarticular, antibiotic, pneumoallergological, vascular area and cardiometabolics. It offers products for neuropsychiatric area, which include anxiety, depression and migraine. Mediolanum provides products for vascular area which include peripheral obliterant arteriopathy and chronic venous insufficiency. The company invests in various patents and projects in areas of endocrinology, rheumatoid arthritis, vaccines for prostate and kidney cancer, and others. Mediolanum is headquartered in Milan, Italy.

Mediolanum farmaceutici SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Mediolanum Farmaceutici Acquires GX301, Therapeutic Vaccine For Treatment Of Cancer, From Genovax 10
Partnerships 12
Acticor Biotech Enters into Research Agreement with Mediolanum farmaceutici 12
Licensing Agreements 13
Mediolanum Enters into Research & Development Cooperation and Licensing Agreement with Apeptico 13
Asset Transactions 14
Biocodex Acquires Non Opthalmic Arm Of Laboratoire Leurquin Mediolanum 14
Mediolanum farmaceutici SpA – Key Competitors 15
Mediolanum farmaceutici SpA – Key Employees 16
Mediolanum farmaceutici SpA – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Key Facts 2
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mediolanum farmaceutici SpA, Deals By Therapy Area, 2012 to YTD 2018 8
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Mediolanum Farmaceutici Acquires GX301, Therapeutic Vaccine For Treatment Of Cancer, From Genovax 10
Acticor Biotech Enters into Research Agreement with Mediolanum farmaceutici 12
Mediolanum Enters into Research & Development Cooperation and Licensing Agreement with Apeptico 13
Biocodex Acquires Non Opthalmic Arm Of Laboratoire Leurquin Mediolanum 14
Mediolanum farmaceutici SpA, Key Competitors 15
Mediolanum farmaceutici SpA, Key Employees 16
Mediolanum farmaceutici SpA, Subsidiaries 17

List of Figures
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mediolanum farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Mediolanum farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析
    Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Regulus Therapeutics Inc (RGLS):企業の財務・戦略的SWOT分析
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target micr …
  • RWE Npower Holdings plc-エネルギー分野:企業M&A・提携分析
    Summary RWE Npower Holdings plc (RWE Npower), a subsidiary of RWE AG, is an energy utility that generates and supplies electricity and distributes gas in the UK. Through its subsidiaries, RWE Npower Group plc and RWE Generation UK plc, the company conducts electricity supply and generation respectiv …
  • The Nisshin OilliO Group Ltd (2602):企業の財務・戦略的SWOT分析
    The Nisshin OilliO Group Ltd (2602) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Annexon Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Annexon Inc (Annexon) is a developer of therapeutic products and pathway inhibitors for the treatment of neurological disorders. The company develops treatments for Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration. Its lead drug candidates inclu …
  • Inivata Ltd:製品パイプライン分析
    Summary Inivata Ltd (Inivata) is a clinical cancer genomics company that utilizes the precision of circulating tumor DNA analysis to improve personalized healthcare in oncology. The company uses liquid biopsy platform, to identify and characterize ctDNA through a non-invasive blood test. Its liquid …
  • MSIG Holdings (Asia) Pte. Ltd.:企業の戦略・SWOT・財務情報
    MSIG Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary MSIG Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Warner Media LLC:企業の戦略的SWOT分析
    Warner Media LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Immucor, Inc.:医療機器:M&Aディール及び事業提携情報
    Summary Immucor, Inc. (Immucor) is an in-vitro diagnostics company, which specializes in the area of pre-transfusion diagnostics. It carries out the development, production and sale of a comprehensive line of reagents and automated systems. The company’s products are used in performing the tests to …
  • Intec Pharma Ltd (NTEC):製薬・医療:M&Aディール及び事業提携情報
    Summary Intec Pharma Ltd (Intec Pharma) is a biopharmaceutical company that offers delivery solutions for drugs. The company’s pipeline products include drug indications for Parkinson’s disease, insomnia and other diseases. Its proprietary gastro retentive formulation, offers a drug delivery solutio …
  • UCB S.A.:企業のM&A・事業提携・投資動向
    UCB S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UCB S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Compuware Corp:企業の戦略・SWOT・財務分析
    Compuware Corp - Strategy, SWOT and Corporate Finance Report Summary Compuware Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Eddie Stobart Logistics plc:企業の戦略・SWOT・財務情報
    Eddie Stobart Logistics plc - Strategy, SWOT and Corporate Finance Report Summary Eddie Stobart Logistics plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Senvion SA-エネルギー分野:企業M&A・提携分析
    Summary Senvion S.A. (Senvion), formerly Senvion S.a.r.l, is a renewable energy company that develops, produces and distributes onshore and offshore wind turbines and towers. It also offers project specific solutions such as turnkey , foundation construction, transport and installation, and service …
  • Auven Therapeutics Management LLLP-製薬・医療分野:企業M&A・提携分析
    Summary Auven Therapeutics Management LLLP (Auven Therapeutics Management), formerly Celtic Therapeutics Management LLLP is a private equity firm that provides life science investment strategy. The firm invests in therapeutic products or platforms. It has invested in diversified portfolio of biologi …
  • Digimarc Corp (DMRC):企業の財務・戦略的SWOT分析
    Summary Digimarc Corp (Digimarc) is a technology company that offers develops solutions, license intellectual property and provides development services to businesses and government. The company offers products such as digimarc discover, online image safeguards and digimarc guardian. Digimarc’s Disc …
  • DCC Plc (DCC):石油・ガス:M&Aディール及び事業提携情報
    Summary DCC Plc (DCC) is a diversified company that offers international sales, marketing, distribution and business support services. The company operates through its business divisions such as LPG, retail, and oil, healthcare and technology. Its LPG business markets liquefied petroleum gas and nat …
  • Royal Mail Plc (RMG):企業の財務・戦略的SWOT分析
    Royal Mail Plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lyft Inc (LYFT):企業の財務・戦略的SWOT分析
    Lyft Inc (LYFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Aeglea BioTherapeutics Inc (AGLE):企業の財務・戦略的SWOT分析
    Summary Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company’s product pipeline comprises AEB1102, AEB …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆